Clinical Report: Evaluating Cystoscope Reprocessing Risks via HFMEA

Overview

Flexible cystoscopy is widely performed but carries infection risks linked to cystoscope reprocessing failures. Using Healthcare Failure Mode and Effects Analysis (HFMEA), critical failure points in the reprocessing workflow were identified and prioritized to enhance patient safety.

Background

Flexible cystoscopy is a common urological procedure requiring high-level disinfection of semicritical cystoscopes to prevent urinary tract infections (UTIs). Infection rates post-cystoscopy vary widely, with inadequate reprocessing significantly increasing patient risk. Despite existing guidelines, compliance with reprocessing standards remains low, necessitating proactive risk assessment methods such as HFMEA. This approach helps identify latent failures in cystoscope reprocessing to mitigate infection risks effectively.

Data Highlights

In one study of 3,108 cystoscopies, 22% developed asymptomatic bacteriuria and 1.9% had clinical UTI. Microbial surveillance revealed contamination rates exceeding 30% in reusable endoscopes, with 12.5% contamination found locally. The HFMEA process involved multidisciplinary team observations over one month, mapping reprocessing steps and quantifying risks via Risk Priority Numbers (RPN) calculated from frequency, severity, and detectability scores.

Key Findings

• Cystoscope reprocessing includes critical steps: pre-cleaning, manual cleaning, high-level disinfection, rinsing, drying, and storage.
• Manual cleaning is the most critical step; residual bioburden compromises subsequent disinfection effectiveness.
• Failure to comply with reprocessing guidelines is common, contributing to contamination and infection risks.
• HFMEA identified multiple failure modes with high RPN scores, prioritizing them for targeted interventions.
• Multidisciplinary team consensus enabled identification of root causes and development of tailored improvement actions.

Clinical Implications

Clinicians and reprocessing staff should emphasize meticulous manual cleaning and strict adherence to established guidelines to reduce infection risks. Implementing HFMEA can proactively identify and mitigate latent failures in cystoscope reprocessing workflows, enhancing patient safety. Regular microbial surveillance and documentation are essential for quality assurance and traceability.

Conclusion

HFMEA is an effective tool to systematically evaluate cystoscope reprocessing risks, enabling prioritization of critical failures and guiding improvements. Addressing these failures can significantly reduce post-cystoscopy infection rates and improve patient outcomes.

References

1. Various Authors/Multiple Years -- Cystoscopy Infection and Reprocessing Literature